Conclusions This retrospective study of pregnancy outcomes from a donor oocyte cryopreservation program suggests that use of cryopreservation of both gametes can achieve good clinical results for infertility patients. It also bodes well for oncology patients who may have either gamete cryopreserved for potential future use. There is no clear explanation for the pregnancy losses when using fresh sperm in these donor oocyte thaw cycles, compared to the cycles where thawed sperm were used. The convenience and efficiency that this total 'cryo-management' of ART cycles cannot be overlooked.
Objective To vitrify primate secondary follicles using closed straws or quartz capillaries, and evaluate follicular function during in vitro culture. Materials and Methods Secondary follicles were isolated from adult rhesus macaque (n=4) ovaries and placed inside 0.25 cc straws in solutions (VS) containing 50% cryoprotectant; VS1: glycerol (GLY) and ethylene-glycol (EG); VS2: GLY, EG+PXZ polymers (polyvinyl-pyrrolodine, polyvinyl-alcohol, polyglycerol); VS3: EG, dimethylsulfoxide (DMSO), sucrose; or VS4: EG, DMSO, sucrose+ PXZ. Straws were heat sealed, vitrified in liquid nitrogen vapor, and warmed with decreasing sucrose concentrations. Ongoing experiments (n=3) are comparing quartz capillaries (30 or 40% VS2) to straws (50% VS2). Fresh and cryopreserved follicles were fixed for histology, cultured with bromodeoxyuridine (BrdU) for DNA synthesis or encapsulated in alginate for in vitro culture.
Results In straws, more follicles survived 5 weeks in vitro with VS1 (62%) and VS2 (65%) relative to VS3 (32%) and VS4 (4%). Antrum formation was greatest in VS2 (50%) compared to VS1 (34%), VS3 (6%) and VS4 (0%). Granulosa cells in follicles from all groups displayed proliferation. Steroid production was highest in VS2 and VS1. Healthy immature oocytes were only obtained in VS1 and VS2. Preliminary data with quartz capillaries showed similar follicle survival, growth and antrum rates compared to follicles vitrified in straws, but those in capillaries displayed antrum 1 week earlier. Steroid and oocyte data are pending.
Conclusions Vitrification with VS2 in a closed system has potential as a novel method for cryopreservation of secondary follicles in primates. Use of quartz capillaries requires further development. Vitrification of secondary follicles followed by in vitro culture would provide a fertility preservation option where ovarian tissue transplantation is contraindicated. S u p p o r t NIH UL1RR024926, R01AHD058293, PL1EB008542, P51RR000163, D43TW000668-Fogarty (JRC)
Oocyte vitrification with closed system Conclusions Our data demonstrate that OC is a feasible FP method, with tailored stimulation protocols and timely treatment through multidisciplinary efforts advancing the field. Continued education, both within and outside our discipline, will ensure that appropriate candidates are offered the opportunity to maintain their fertility and potential for parenthood. Support None.
Effect of blastocoel aspiration before vitrification on subsequent blastocyst survival and development: mouse model study Objective Embryo developed to blastocyst stage produces blastocoel in its cavity. It is unclear whether the presence of blastocoel in the cavity affects the blastocyst survival and subsequent development after frozenthawing. Therefore the purpose of the present study was to evaluate the potential effect of blastocoel aspiration prior to vitrification on subsequent blastocyst survival and development. Materials and Methods A total of 121 mouse blastocysts (day 5) were vitrified using two-step protocol in the study. Briefly, the blastocysts were transferred to equilibration solution containing 7.5% ethylene glycol (EG) and 7.5% propandiol (PROH) for 3 min at room temperature, and then transferred to vitrification solution containing 15% EG and 15% PROH and 0.5 M sucrose for 1 min. Then 5 blastocysts were loaded on JY Straw and plunged into liquid nitrogen directly. Before vitrification, the blastocysts were randomly divided into two groups: (1) 61blastocysts were vitrified without intervention; (2) 60 blastocysts were vitrified with blastocoel aspiration before cryopreservation. For thawing, the blastocysts were inserted to thawing solution (TS) 1 containing 1.0 M sucrose and transferred the blastocysts to TS2 (0.5 M sucrose), TS3 (0.25 M sucrose) for 3 min respectively, and then washed twice with culture medium before developing culture. After thawing, the blastocysts were examined with survival rate and hatching rate following 24 h of culture. In addition, DNA damage of blastomeres was evaluated by the method of terminal deoxynucleotide transferase (TdT)-mediated dUTP-digoxigenin nick-end labeling staining at the end of development culture. Results The largest distinct cohort included 40 breast cancer patients that were treated with high-dose FSH (150-450U/day) and letrozole (5 mg/day) in a long GnRH-agonist (n=7) or GnRH-antagonist (n=37) protocol. In 3 additional cases, a natural cycle IVF was performed. In two cases, tamoxifen was used alone or with FSH injections. Overall, for this group, the average interval from surgery to oocyte retrieval was 40 days. Average duration of treatment was 8.6 days, and mean peak E2 level was 1294 pmol/l (200-3187), yielding a mean number of 12.0 aspirated oocytes (0-82), and mean number of 7.8 embryos cryopreserved (0-45). Standard IVF treatment, usually performed in younger cancer patients (mostly with lymphomas), yielded on average 13.2 oocytes (2-33) and mean number of 7.0 (0-14) embryos cryopreserved. In another 6 patients, urgent IVM was performed; On average, 10 oocytes (8-12) were retrieved, with maturation rate of 12.5-66% (mean 52%), and mean fertilization rate of 58% (0-100%, median 71%).
Overall 0-5 (mean 2, median 1.5) zygotes were cryopreserved. In one case 6 oocytes were vitrified. Conclusions Ovarian stimulation with letrozole and highdose FSH is apparently effective in breast cancer patients and spares them exposure to high E2 levels. The results of urgent aspiration of small follicles and IVM for fertility preservation are inferior to that observed in planned IVM cycles.
Life birth rate after aseptic vitrification of mii oocytes in closed carrier devices In order to bypass direct contact with LN2 closed tools may be applied. Despite good results for zygotes and blastocysts in closed carriers, it is widely believed that it is impossible to vitrify oocytes in closed tools due to reduced cooling conditions. The aim of our study was to proof the safe clinical application aseptic oocyte vitrification, but also in beforehand to confirm the feasibility of vitrification under reduced cooling rates. Materials and Methods Behavior of mouse oocytes during the vitrification process was performed in cinematographic analysis. After analysis of these data a protocol for aseptic vitrification of oocytes was established. Subsequently, the efficiency in the closed system was proofed in human oocytes. Results In 55 cycles 423 aseptic vitrified oocytes were thawed and a survival rate of 84.9% was obtained. The fertilization rate was 78.8% and a cleavage rate of 94.7% on d3 was observed. After transfer 24/55 patients were pregnant resulting in 20 deliveries (36.4%). Conclusions This study proofs that it is possible to work with aseptic carriers for vitrification of oocytes without impairing survival and developmental potential. Especially with the more and more applied technique of oocyte vitrification in fertility preservation programs where the oocytes might be stored for many years or even 1-2 decades the ability to work with closed straws which can be stored in LN2 safely without the endangerment of cross-contamination during storage this might be of major impact. Support None Randomized Controlled Trial (RCT) of Slow Freeze (SF) and Vitrification (Vit) for Oocyte Cryopreservation (OC): A preliminary report of ongoing pregnancy rates Objective To identify if SF or Vit for OC is superior. Method An RCT in infertility patients for OC with SF or Vit with subsequent thaw/warming cycles evaluated recovery, survival rates, fertilization rates, cleavage rates, blastocyst rates, clinical pregnancy (CPR) and ongoing pregnancy rates (OPR). Data from patients who electively chose OC by one method only (9 SF and 1 Vit) and a recipient who used frozen donor eggs half SF and half Vit is included. NYU IRB #06-749. Result Six patients randomized with eggs frozen by either SF or Vit (mean age-34.3 vs 33) completed cycles. All eggs were thawed (107), fertilized by ICSI, cultured in an extended media and 1-2 embryos transferred during a standardized replacement cycle. Recovery rates 94% SF, 79% Vit; P=0.02, fertilization rates 80% (28/35) SF, 79% (26/33) Vit: P=1.00, cleavage rates 79% (22/28) SF, 100% (26/26) Vit: P=0.024, blastocyst rates 29% (8/28) SF, 35% (9/26) Vit; P=0.771 and CPR (1/3 SF, 3/3 Vit) and OPR (0/3 SF and 3/3 Vit) were not different (P=0.100). Including a recipient cycle who had SF only resulting in miscarriage and subsequently Vit only (eggs from the same donor cycle) resulting in an ongoing pregnancy, then the OPR are statistically different 0/4 SF vs. 4/4 Vit; P=0.0286 with same mean age. If one includes 9 patients who had thaw of SF oocytes only 2/10 ongoing pregnancy rate-1 patient had 2 thaws and 1 recipient who had Vit only with an ongoing pregnancy then the data is in favor of Vit (2/14 SF vs. 5/5 Vit; P= 0.0018). Excluding 3 of the 9 patients who had SF only because of age> 39, the data is still significant 1/10 SF, 5/5 Vit; P= 0.002 with no mean age difference. Conclusion The limited data from the randomized controlled trial is too small to be conclusive. However, including data from patients randomly choosing SF or Vit, the data favors Vit over SF. Changing from Cryotip to Cryolock during Vit has improved recovery rates from 79% to 92%.
Oocyte cryopreservation (OC) pregnancy after embryo biopsy with preimplantation genetic screening (PGS) by array CGH (a-CGH) for aneuploidy: proof of concept
Objective To report a pregnancy from embryo biopsy using cryopreserved oocytes. Methods We report a case of PGS using vitrified warmed oocytes in a 38-year-old woman. The husband developed azoospermia secondary to sepsis and a prior PGS cycle using previously cryopreserved sperm had resulted in all aneuploid embryos. One year later when the ejaculate had motile sperm it was used for an oocyte thaw/warming cycle and PGS. Results The patient had a normal d2 FSH, a vigorous response to gonadotropins. In the first attempt using cryopreserved sperm 32 mature oocytes were fertilized by ICSI and 6 embryos were biopsied and all were found to be abnormal (mostly complex abnormal). Five probe FISH analysis of sperm revealed 3% aneuploidy that is 30 times normal and possibly caused the aneuploidy. A second stimulation cycle was performed. Oocytes were cryopreserved, 13 by vitrification and 15 by slow freeze. One year later there were motile sperm in fresh semen. All 28 oocytes were thawed and ICSI was performed using a fresh sample, 17 fertilized and 16 progressed to day 3 when blastomere biopsy was performed. Three embryos were euploid (all from vitrification) and two were transferred. A day 28 b-hcg was 108 and a day 35 b-hcg was 495 in a different lab. Ultrasound showed endometrial thickening but no definite sac or evidence of ectopic. Bleeding occurred on day 38 and b-hcg levels normalized. Conclusions PGS has been widely used for recurrent miscarriage, aneuploidy screening for advanced maternal age and family balancing. There have been no reports of PGS on embryos derived from cryopreserved oocytes. However, as OC continues to gain popularity there will be more indications for PGS using cryopreserved oocytes. Despite the outcome, this case provides proof of concept that PGS after OC is possible. As more women freeze their eggs and as more recessive genes are discovered the need for successful PGs after OC will increase. Objective Two step method, including equilibration solution and vitrfication solution, is the most popular technique for oocyte vitrification in the published paper. But the survival rate is significantly different among different IVF centers and the efficiency is extensively controversial. The purpose of this study is to develop a stable and efficient method for oocyte vitrification. Materials and Methods 434 Kunming mouse oocytes (a kind of widely used Chinese strain mouse) were used in this study. We compared the survival rate (SR), cleavage rate (CR), blastulation rate (BR) and hatching rate (HR) in 5 groups as follows. A: fresh group (88 oocytes); B: Conventional toxic group (89 oocytes), 7.5% ethylene glycol (EG)+7.5% dimethyl sulfoxide (DMSO) (Equilibration solution = ES), 15% EG+15% DMSO+0.5 M sucrose (S) (Vitrfication solution = VS), no plunged into liquid nitrogen (LN), C: 0.2 M sucrose pretreatment toxic group (83 oocytes), 0.2 M S, 7.5% EG + 7.5% DMSO + 0.2 M S (ES), 15% EG + 15% DMSO + 0.5 M S (VS), no plunged into LN, D: Conventional vitrfication group (87 oocytes), B group using home-made strawtop vitrification and warming, E: 0.2 M sucrose pretreatment vitrification group (87 oocytes), C group using strawtop vitrification and warming. 1 M, 0.5 M and 0 M sucrose solutions were used for cryoprotectants dilution step by step. All vitrification and warming steps were performed at room temperature except the first warming step at 37°C. 310 1-day-old fertilization failure human oocytes were used for SR research by group D and E (155 oocytes each group) obtained with patients' informed consent. Results For mouse oocytes, SR, CR, BR and HR were 100% (88/88), 93.2% (82/88), 69.5% (57/82) and 64.9% (37/57), 100% (89/89), 92.1% (82/89), 67.1% (55/82) and 52.7% (29/55), 100% (83/83), 90.4% (75/83), 73.3% (55/ 75) and 56.4% (31/55), 95.4% (83/87), 88.0% (73/83), 65.8% (48/73) and 54.2% (26/48), 100% (87/87), 85.1% (74/87), 75.7% (56/74) and 50% (28/56) in groups A, B, C, D and E, respectively. There were no significant differences among the 5 groups. For human oocytes, SR of group E (155/155=100%) was significantly higher than group D (140/155=90.3%, p<0.001). Conclusions Sucrose pretreatment vitrification method was a promising technique for Kunming mouse vitrification. More research need to be performed on human mature oocytes developmental competence for this method. Support This work was supported by Laboratory of Molecular Cell Biology, Chinese Academy of Science, Shanghai and the Natural Science Foundation of Shanghai, China (Grant No.09ZR1417000).
Oocyte crypreservation in women affected by endometriosis before surgical treatment. A pilot study Marco Sbracia, MD, Antonio Colicchia, MD, Daniela Marconi In order to preserve the fertility of women with bilateral endometriotic ovarian cysts undergoing laparoscopic surgery we proposed to these patients the possibility to cryopreserve oocytes before the surgery. In this paper we reported the preliminary data of our program to preserve fertility in endometriois women. A total of ten women with bilateral ovarian endometriotic cysts accepted to undergo to this program: they underwent to stimulation protocol with Letrazole plus FSH. The women from the first day of menstrual cycle for 5 days were treated with 5 mg/day of Letrazole (Femara 2.5 mg, Novartis, Italy), and from the third day they underwent to urinary FSH (Fostimon, IBSA, Italy) supplementation at the dosage of 225 IU/day. After sonographic monitoring the FSH dosage was adjusted according to the patient response, from the 7th day of treatment. When the leading follicle >14 mm or the plasmatic estradiol was higher than 300 pg/ml Cetrorelix (Cetrotide 0.25 mg, Merck Serono, Italy) was administered to the patients until the ovulation induction. The ovulation was triggered by triptorelin injection when at least 3 follicles were bigger than 16 mm in mean diameter. A total of 13 oocyte retrievals were performed in ten women, with 88 oocytes collected, 81 of them were metaphase II, and a total 79 oocytes were cryopreserved by vitrification. In each patient at least three mature oocytes were obtained with a median of 5 (range 3-10). No severe complication were observed, except abdominal discomfort in 2 cases and one case of mild OHSS. At the moment none of the patient decide to utilize the cyropreserved oocytes for IVF cycle, Our study showed the feasibility of fertility preservation program in these patients. Objective To determine if blastocysts from previously frozen mouse embryos are a suitable model to practice for the vitrification of human embryos/oocytes Materials and Methods A total of 58 commercially available frozen 1 cell mouse embryos (B6D2F1XB6C3F1) were cultured to blastocyst (94% rate after first thaw) to be used to establish a vitrification program in our IVF laboratory. Only expanded blastocysts were used. All embryos were vitrified and thawed during two separate attempts, using purchased DMSO-free cooling/warming media (Medicult, Denmark) in closed and open devices. In general, manufacturer's protocols were followed for both the vitrification and warming procedures. Both times, survival (SR) and developmental rates (DR) of embryos were evaluated immediately after thawing (at start of warming procedure-T0), rinsed and cultured in HTF-like medium (cleavage medium-Sage; Cooper Surgical; U.S. A.) for 24 h. Additional evaluations were done at 2 and 24 h post-warming (T2 and T24, respectively). Results The overall SR of both attempts combined were 70.6 at T0, 58.5 at T2 and 34.3% at T24 (18.9% of embryos were not recovered and 10.3% degenerated). When results were analysed for Vitrification Attempt [1, n=26 versus (vs.) 2, n=32], no significant differences were seen in these rates at T0 (76.9 vs. 65.6), or at T2 (53.8 vs. 62.5) and T24 (38.4 vs. 31.2%). When re-analysed for Warming Attempt (1, n=13 vs. 2, n=45), we observed, on average, a higher SR at T0 after Attempt 2 compared to 1 (75.5 vs. 53.8) and T24 (40.0 vs. 15.3%). We also observed a numerically higher DR for Warming Attempt 2 (26.6 vs. 15.3%). We did, however, see a significant increase in the SR at T2 for Attempt 2 vs. 1 (64.4 vs. 23.0%; p=021). Conclusion Commercially frozen mouse embryos can provide essential information for initiating a Vitrification program for human embryos and oocytes. The Warming procedure appears to be more learning curve-sensitive than the Vitrification itself. Support The Foundation for Medical Reproduction, Voorburg and the Research Division of the Reinier de Graaf Group, Delft, The Netherlands Live births from embryos vitrified at the cleavage stage: impact of maternal age Soto E and Desai N Cleveland Clinic Fertility Center, Department of OB/GYN, Beachwood, OH Objective To examine the relationship between maternal age at cryopreservation and live birth rates.
Materials and Methods
Cleavage stage embryos (6-8 cells) with <20% fragmentation were selected for vitrification. Embryos were vitrified on cryoloops using a two-step protocol: (1) 7.5% DMSO/ethylene glycol (EG) with sucrose for 2 min followed by (2) 15% DMSO/EG for 45 s before immersion in LN2. Warming was performed at 37°C in culture medium with 0.25 M sucrose. Patients were prepared for frozen embryo transfer using estradiol and intramuscular progesterone. Clinical pregnancy was confirmed by presence of a fetal heart rate on ultrasound at 6-8 weeks gestation. Clinical pregnancy, implantation and live birth rates were compared across age groups. Data was analyzed using the one-way ANOVA and chi square test. Results A total of 361 thaws were performed between 2005-2009 at the Cleveland Clinic Fertility Center. Average patient age was 33±4. Eight thaw cycles had no embryo survival. Outcomes are delineated in Table 1 . Objective Aggressive chemotherapy and radiotherapy have greatly enhanced the life expectancy of young cancer patients, but these treatments cause massive destruction of the ovarian reserve resulting in infertility or sterility. However, oocyte cryopreservation can preserve their fertility of these patients after cancer treatment. We applied a minimal ovarian stimulation protocol using clomiphene citrate (CC) to retrieve mature oocytes, and the cryotop vitrification method to cryopreserve them. Materials and Methods Sixty-four unmarried hematopoietic defect patients with informed consent who underwent the CC cycle from January, 2007 to July, 2011. Fifty mg CC was administered from cycle day 3 and 75 IU HMG was administered every other day from day 8 until the leading follicle developed to 18 mm in diameter. Administration of CC was then stopped, and 300 g GnRH-agonist was given as a maturation trigger. Oocytes were retrieved from 30 to 36 h following the administration of the GnRH-agonist using a 22 gauge needle with local anesthesia. The retrieved oocytes were denuded before vitrification. The cryotop method was used to vitrify the oocytes (Kuwayama 2005) .
Results The type of cancers included acute and chronic leukemia, malignant lymphoma, aplastic anemia, and myelodysplastic syndrome. The mean age of the patients was 26.3 (± 5.2, S.D.). The mean number of retrieved oocytes per cycles was 3.7, and the mean number of morphologically normal cryopreserved oocytes per cycle was 3.1. The mean numbers of oocyte retrieval cycles per patient was 1.7. The mean number of morphologically normal cryopreserved oocytes per patient was 5.5. No patients had any adverse side effects. Conclusion Our data showed that the minimal ovarian stimulation protocol using CC for oocyte retrieval with a 22 gauge needle and with anesthesia was a safe, simple, effective method of preserving fertility for unmarried cancer patients.
